Literature DB >> 9186990

Sleep apnea in sarcoidosis.

G A Turner1, E E Lower, B C Corser, K L Gunther, R P Baughman.   

Abstract

BACKGROUND AND AIM OF WORK: Sleep apnea is reported to occur in 2-4% of the general population. Patients with sarcoidosis are at increased risk for sleep apnea, possibly due to factors such as steroid use, neurosarcoid, or upper airway obstruction.
METHODS: In order to determine the prevalence and risk factors for sleep apnea in sarcoidosis patients, we studied 83 consecutive patients with sarcoidosis seen over a six-week time period. Patients were screened using the Epworth Sleepiness Scale questionnaire and the age, sex, race, weight, and medications were recorded. The presence of previously diagnosed sleep apnea, neurosarcoid, lupus pernio, and sinus disease were also noted. A control group of 91 patients seen in general pulmonary clinics were similarly screened. Patients with a positive sleep questionnaire were referred for sleep studies.
RESULTS: A total of 14 sarcoid patients (17%) were found to have sleep apnea, which was significantly higher than our control group with 3/91 (3%, p < 0.001). The presence of lupus pernio was significantly more frequent in the sleep apnea group. Although 5/51 (10%) female sarcoid patients had sleep apnea, overall it was more frequent in male sarcoid patients.
CONCLUSIONS: Sleep apnea was frequent in sarcoid patients and was associated with lupus pernio.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186990

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  16 in total

Review 1.  Patient reported outcome measures (PROMs) in sarcoidosis.

Authors:  Rikke Flor Thunold; Anders Løkke; Adam Langballe Cohen; Hilberg Ole; Elisabeth Bendstrup
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Obstructive sleep apnea in patients with interstitial lung diseases: past and future.

Authors:  Charalampos Mermigkis; Izolde Bouloukaki; Sophia E Schiza
Journal:  Sleep Breath       Date:  2013-04-12       Impact factor: 2.816

Review 3.  Sleep disordered breathing in interstitial lung disease: A review.

Authors:  Lauren K Troy; Tamera J Corte
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

4.  Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.

Authors:  Elyse E Lower; Atul Malhotra; Victoria Surdulescu; Robert P Baughman
Journal:  J Pain Symptom Manage       Date:  2012-08-20       Impact factor: 3.612

Review 5.  Pulmonary hypertension caused by sarcoidosis.

Authors:  Enrique Diaz-Guzman; Carol Farver; Joseph Parambil; Daniel A Culver
Journal:  Clin Chest Med       Date:  2008-09       Impact factor: 2.878

6.  Obstructive sleep apnea is common in patients with interstitial lung disease.

Authors:  Aylin Pihtili; Zuleyha Bingol; Esen Kiyan; Caglar Cuhadaroglu; Halim Issever; Ziya Gulbaran
Journal:  Sleep Breath       Date:  2013-04-08       Impact factor: 2.816

7.  Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment.

Authors:  Heng Duong; Catherine A Bonham
Journal:  Clin Pulm Med       Date:  2018-03

Review 8.  Measures of sleep in rheumatologic diseases: Epworth Sleepiness Scale (ESS), Functional Outcome of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI).

Authors:  Theodore A Omachi
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

9.  Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis.

Authors:  Charalampos Mermigkis; Jeffrey Chapman; Joseph Golish; Demetrios Mermigkis; Kumaraswamy Budur; Antony Kopanakis; Vlassis Polychronopoulos; Richard Burgess; Nancy Foldvary-Schaefer
Journal:  Lung       Date:  2007-04-10       Impact factor: 3.777

Review 10.  The Bidirectional Relationship between Sleep and Immunity against Infections.

Authors:  Elizabeth G Ibarra-Coronado; Ana Ma Pantaleón-Martínez; Javier Velazquéz-Moctezuma; Oscar Prospéro-García; Mónica Méndez-Díaz; Mayra Pérez-Tapia; Lenin Pavón; Jorge Morales-Montor
Journal:  J Immunol Res       Date:  2015-08-31       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.